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ARTICLE
Selective N-terminal acylation of peptides and
proteins with a Gly-His tag sequence
Manuel C. Martos-Maldonado1,2, Christian T. Hjuler 1,2, Kasper K. Sørensen1,2, Mikkel B. Thygesen 1,2,
Jakob E. Rasmussen1,2, Klaus Villadsen1,2, Søren R. Midtgaard 3, Stefan Kol4,
Sanne Schoffelen1,5 & Knud J. Jensen 1,2
Methods for site-selective chemistry on proteins are in high demand for the synthesis of
chemically modiﬁed biopharmaceuticals, as well as for applications in chemical biology,
biosensors and more. Inadvertent N-terminal gluconoylation has been reported during
expression of proteins with an N-terminal His tag. Here we report the development of this
side-reaction into a general method for highly selective N-terminal acylation of proteins to
introduce functional groups. We identify an optimized N-terminal sequence, GHHHn− for the
reaction with gluconolactone and 4-methoxyphenyl esters as acylating agents, facilitating the
introduction of functionalities in a highly selective and efﬁcient manner. Azides, biotin or a
ﬂuorophore are introduced at the N-termini of four unrelated proteins by effective and
selective acylation with the 4-methoxyphenyl esters. This Gly-Hisn tag adds the unique
capability for highly selective N-terminal chemical acylation of expressed proteins. We
anticipate that it can ﬁnd wide application in chemical biology and for biopharmaceuticals.
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Methods for site-selective modiﬁcation of peptides andproteins are required for different ﬁelds, such as thedevelopment of biopharmaceutical conjugates (e.g.,
PEGylation, lipidation, and antibody–drug conjugates)1, bioima-
ging2, medical diagnostics3, and material sciences4. Most proteins
display multiple copies of the same side-chain at different loca-
tions. Reactions that target a particular functional group, e.g., the
primary amine in Lys or thiol in Cys, potentially modify all
occurrences of this residue, leading to the formation of a het-
erogeneous mixture of modiﬁed protein. Reactions involving
proteins must also proceed in aqueous solutions under mild pH
and temperature. These factors make it challenging to modify
proteins in a regioselective manner. Several strategies have been
developed to address this challenge. Some methods rely on
genetic code expansion5–7, which allows for the site-speciﬁc,
ribosomal incorporation of non-canonical amino acids that
exhibit suitable functionalities for bioorthogonal chemistry8,9.
However, selective chemical methods applicable to proteins
consisting of only canonical amino acids are an attractive alter-
native, as these proteins can be produced using standard, higher-
yielding expression methods.
N-termini of proteins tend to reside on the surface of proteins10
and are thus often well accessible to chemical modiﬁcation11. Also,
they can often be extended with additional amino acids without
interference with protein function11. The N-terminal α-amine can
be targeted for selective, pH-controlled acylation or alkylation due
to its pKa value that is lower (pKa 7.6–8.0) than for Lys side-chain
ε-amines (pKa 10.5 ± 1.1)12. Nevertheless, the selectivity is often
challenged by the presence of a high number of competing
ε-amines on Lys residues and the fact that their pKa can be lower
due to the local environment. Also, direct acylation with NHS
esters and reductive alkylation require a low-to-neutral pH.
Alternatively, particular amino acids can be speciﬁcally targeted
when located at the N-terminus, such as Cys via native chemical
ligation13 or 2-cyanobenzothiazole (CBT) condensation chem-
istry14, Trp via Pictet–Spengler reactions15,16, Ser and Thr via
periodate oxidation to yield aldehydes for subsequent conjugation
with α-nucleophiles17–20, or Pro via oxidative coupling with
aminophenols21,11. A small number of more general approaches
for site-selective N-terminal modiﬁcation without speciﬁc residue
requirements have been described. A site-selective diazotransfer
reaction for azide introduction has been achieved with imidazole-
1-sulfonyl azide at pH 8–8.522, a phenyl ketene derivative has been
used for alkyne introduction23, a transamination reaction with 2-
pyridinecarboxyaldehydes has been reported24, as well as reduc-
tive alkylation25. In addition to these methods for N-terminal
labeling, the use of a four amino acid sequence (Phe-Cys-Pro-Phe)
that enhances the reactivity of its cysteine residue for site-selective
reaction with perﬂuoroaryl compounds has been reported26.
Other small peptide sequences with high afﬁnity for molecules of
interest, e.g., ﬂuorophores, have been reported. For instance, a
tetracysteine tag (Cys-Cys-Xxx-Xxx-Cys-Cys) for selective
reaction with an arsenic-modiﬁed ﬂuorescein derivative26,27
and a tetraserine motif (Ser-Ser-Pro-Gly-Ser-Ser) that binds a
rhodamine-derived bisboronic acid28.
Polyhistidine tags (His tags) are widely used for protein pur-
iﬁcation by immobilized-metal ion afﬁnity chromatography29.
However, it has been reported that during their expression His-
tagged proteins can undergo N-terminal acylation with D-glu-
conic acid δ-lactone (GDL, 1) as an inadvertent side-reaction30.
Geoghegan et al. observed gluconoylation of proteins when
expressed in Escherichia coli, while using His tags with the N-
terminal sequence GSSHHHHHHSSGLVPR–. They also reported
that synthetic peptides GSSHHHHHHSSGLVPR, GSAHHH
HAAR, GASHHHHAAR, and GAAHHHHAAR could be mod-
iﬁed with GDL in HEPES buffer at pH 7.530.
Here, we convert an undesirable side-reaction into a highly
selective chemical method for modiﬁcation of peptides and pro-
teins (Fig. 1). We identify an optimal N-terminal sequence
(GHHHn) using GDL as inexpensive, water-soluble acylating
agent. Studying the reactivity with other acylating agents, 4-
methoxyphenyl esters gave good selectivity for acylation of this
N-terminal tag. 4-Methoxyphenyl esters facilitate the introduc-
tion of small reactive groups, such as azides, or the direct con-
jugation of functional molecules such as biotin. We demonstrate
the potential on several peptides and proteins. The GHHHHHH
tag, which can be fused to the N-terminus of any protein of
interest, offers a dual functionality His tag as it can still be used
for afﬁnity puriﬁcation. We believe that this methodology will be
a valuable contribution to the toolbox for N-terminal modiﬁca-
tion. We propose the name His tag acylation to describe this
method.
Results
D-Gluconic acid δ-lactone for peptide modiﬁcations. We
hypothesized that highly site-selective gluconoylation of the Nα-
amine could be achieved with an optimized N-terminal sequence.
We synthesized 11 peptides with different N-terminal tags
attached to the sequence LRFKFY-NH2 (Table 1). All peptides
included one Lys residue to test the selectivity of the reaction for
the N-terminal α-amine. The peptides were treated at a con-
centration of 1 mM in 200 mM HEPES buffer at pH 7.5 with 25
equiv. of GDL (1) at room temperature.
The base peptide sequence LRFKY-NH2 (2) by itself, which has
an N-terminal Leu and a Lys with an ε-amino side-chain, was
practically resistant to N-terminal acylation (Table 1). Addition of
a Gly residue with a non-hindered α-amine (3, 4) increased the
degree of N-acylation somewhat. Addition of N-terminal His
residues to give peptides 5 and 6 signiﬁcantly improved N-
acylation. Also, the presence of three His was beneﬁcial (5 vs 6).
N-terminal addition of Gly to His improved the N-acylation (5 vs
7) further, while a Ser30 in between Gly and His was detrimental
(7 vs 8). Increasing the number of His from Gly-His to Gly-His-
His-His (4, 9 vs 10) provided a clear improvement in propensity
to be acylated by GDL. Additional control experiments conﬁrmed
the importance of a sterically non-hindered Gly α-amine N-
terminally of the His-His-His, as corresponding peptides with N-
terminal Ala and Val proved increasingly resistant to N-acylation
(6, 11, 12 vs 10).
Formation of di-gluconoylated products of these peptides was
not observed in any case, which pointed towards a site-selective
modiﬁcation of the N-terminal α-amine. To further substantiate
this, the selectivity of the reaction was analyzed in the case of
peptide 9. NMR spectroscopy conﬁrmed that the reaction took
place selectively at the N-terminal α-amine and not on the ε-
amine of the Lys residue (Supplementary Fig. 1).
Encouraged by these observations, we evaluated the optimized
GHHH sequence in the 18-mer peptide 13 (DWLKAFYDK-
VAEKLKEAF, Beltide-1), which has four Lys residues. Beltide-1 is
an amphipathic helical peptide that self-assembles to give lipid
ﬁlled nanodiscs31. The obtained results with model peptides 2–12
suggested that the optimal N-terminal sequence for site-selective
gluconoylation was GHHHn– (where n ≥ 1). Commonly used His
tags for protein puriﬁcation by immobilized-metal ion afﬁnity
chromatography can be placed N- or C-terminally and typically
contain six His residues29. We hypothesized that adding extra His
residues to GHHH could improve the ability to be acylated. We
compared GHHH- with GHHHHHH-tags on a Beltide-1 peptide
sequence (Table 2). First, control experiments with non-tagged
Beltide-1 (13) and its acetylated analog (13Ac) did not show any
peptide acylation. Next, GHHH-Beltide-1 (14) was N-acylated in
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73%, while GHHHHHH-Beltide-1 (15) showed higher reactivity
and reached full conversion to the corresponding mono-
gluconoylated derivative after 1 h, when treated at a concentration
of 1 mM with 100 equiv. of GDL in 200mM HEPES buffer at pH
7.5 at room temperature (Supplementary Fig. 2). Remarkably,
formation of di-gluconoylated peptides was not detected.
Importantly, in a control experiment we observed that N-
terminally acetylated peptide Ac-GHHHHHH-Beltide-1 (15)
was not acylated by GDL, which again indicated that the reaction
occurred selectively at the N-terminal α-amine, when
available.
Phenyl esters as acylating agents. While other acylating agents,
including lactones, thioesters, and a N-hydroxysuccinimide ester
were also tested (Supplementary Fig. 3), they only gave limited N-
terminal acylation or low selectivity. We then focused on tuning
the properties of representative phenyl esters 16–18 (Fig. 2). The
4-nitrophenyl and unsubstituted phenyl esters proved too reactive
and were not selective in the acylation, whereas 4-methoxyphenyl
ester 18 provided good selectivity while retaining reactivity. The
half-life of 18 in 200 mM HEPES buffer, pH 7.5, at 4 °C was 3.8 h
(Supplementary Fig. 4).
When GHHHHHHH-Beltide-1 (15) at 1 mM was reacted with
2.5 equiv. of 18 at 4 oC for 24 h, full conversion was achieved
(92% mono-acylated (15Az) and 8% di-acylated peptide) (Table 3,
Supplementary Fig. 5 and 6). Shorter reaction time or lower
equiv. led to exclusive formation of mono-acylated peptide,
although with lower conversion. The same conditions were tested
on other Beltide-1 derivatives (Table 3). GHHHHHH-Beltide-1
(15) and GHHHHHHG-Beltide-1 (15G) showed higher reactivity
and selectivity than GHHH-Beltide-1 (14). The beltide sequence
has four Lys (position 4, 9, 13, and 15). Trypsin digestion of the
diacylated product (15Az-Az) showed that the second acylation
had occurred chieﬂy at Lys-4, located most closely to the His
acylation tag (Supplementary Fig. 7 and 8). The small difference
between 15 and 15G could point to a minimal effect of the
additional spacing of Lys-4 and the His acylation tag provided by
the Gly, in this particular case.
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Fig. 1 Concept for N-terminal His tag acylation of Gly-Hisn sequences. a Optimization of the His tag sequence for acylation with GDL; b identiﬁcation of 4-
methoxyphenyl esters as functional acylating agents; and c application of the His tag acylation to proteins
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In 15K and 15K-Ac an additional Lys was placed C-terminal of
the GHHHHHH sequence to study the selectivity with a Lys Nε-
amine close to His acylation tag. Treatment of 15K with 18 gave a
slightly elevated level of diacylation (14%), while for N-terminally
blocked 15K-Ac an acylation of 31% was observed. This showed
that while the His acylation tag can promote reaction at a
neighboring Lys Nε-amine it has a high selectivity for N-terminal
acylation.
Protein modiﬁcations. The optimized N-terminal sequence
GHHHHHH (GH6) and the conditions for acylation were then
evaluated on proteins. First, we employed GDL to modify three
GH6-tagged proteins, enhanced green ﬂuorescent protein (EGFP,
30.8 kDa), maltose binding protein (MBP, 41.0 kDa) and a small
ubiquitin-related modiﬁer protein (SUMO, 12.5 kDa). EGFP is
known for its intrinsic ﬂuorescence and is widely used as model
protein. MBP, a protein which is part of the maltose/maltodextrin
system of E. coli, is commonly used to increase the solubility of
recombinant proteins by generation of an MBP-protein fusion.
SUMO proteins, structurally related to ubiquitin, modify the
function of the proteins to which they are conjugated. Like MBP,
they are also used as fusion tag to enhance expression and
solubility of recombinant proteins. The three model proteins
contain 21, 35, and 9 Lys residues, respectively. The GH6-tagged
proteins were successfully expressed in E. coli. Both EGFP and
MBP were puriﬁed by Ni2+ afﬁnity chromatography, which
conﬁrms that this GH6-tag still functions as puriﬁcation tag.
Rewardingly, the reactions with GDL yielded only the mono-
functionalized proteins in all cases, as can be seen in Fig. 3a.
As determined by MALDI-TOF MS, trypsination of gluconoy-
lated GH6-EGFP yielded the gluconoylated N-terminal fragment
(amino acids 1–14) (Fig. 3b). Only the unmodiﬁed version of
tryptic fragment #29–276 was detected by ESI-TOF MS,
indicating that none of the 20 Lys residues located in this
fragment were modiﬁed. Furthermore, digestion with chymo-
trypsin showed that fragment 20–29 (m/z= 1158.623) was
detected but not its gluconoylated version, which revealed that
Lys21, the only Lys residue in the ﬁrst 28 amino acids of the
protein, had remained unmodiﬁed. Taken together, these
observations indicated that the modiﬁcation with GDL occurred
exclusively at the N-terminus of EGFP.
Interestingly, for both 15 and GH6-EGFP the gluconoylation
proved to be reversible (Supplementary Fig. 9 and 10). We
hypothesize that the reversibility can be due to the polyol
structure in the gluconoylated protein, however, this would
require additional studies. In contrast, the acylation with 4-
methoxyphenyl esters of acetic acid derivatives gave stable
products (Supplementary Fig. 11 and 12).
For comparison, additional experiments were carried out with
GSSH6-EGFP, which has a conventional His tag, as well as non-
tagged GSH-EGFP. In both cases, some formation of mono-
gluconoylated product was observed, although with signiﬁcantly
lower conversion in comparison to GH6-EGFP (Fig. 3c). These
results highlighted the importance of our His acylation tag for the
reaction to occur. GH6-EGFP and GSSH6-EGFP are identical
except for the two inserted Ser residues; thus, these data
conﬁrmed the importance of an uninterrupted N-terminal Gly-
His sequence.
Next, the 4-methoxyphenyl ester 18 was used to modify GH6-
EGFP. Gratifyingly, 18 was effective in labeling the protein at 4 °
C. When a 35 µM solution of GH6-EGFP in 200 mM HEPES
buffer at pH 7.5 was treated with 40 equiv. of 18 for 4 days,
followed by the addition of two aliquots of 10 equiv. of 18 in the
next two days, 88% conversion was observed by ESI-MS (71%
conversion to mono-functionalized products) (Fig. 4b). Here it
should be noted that the 4 days incubation time can be shortened
to one day. In follow-up experiments and in agreement with the
observed half-life of 18 at 4 °C (see above), it was observed that
no additional acylation occurred after one day, unless a fresh
portion of phenyl ester 18 was added. In a second scenario for
optimization, fewer equivalents and shorter reaction times
resulted in a somewhat lower overall conversion, but also in a
higher selectivity towards the mono-functionalized species. For
example, when the protein was treated with 20 equiv. of 18 for 1
day, 51% was converted and 45% was mono-functionalized
(Supplementary Fig. 13).
Azido-functionalized N3-CH2-C(O)-GH6-EGFP was reacted
with DBCO-OEG4-biotin (19, Fig. 4) to demonstrate the potential
of the strategy for subsequent strain-promoted alkyne–azide
conjugation. ESI-MS analysis displayed predominant formation
of the mono-labeled protein (Fig. 4c). The sample was digested
with trypsin and subsequently analyzed by MALDI-TOF MS. The
labeled N-terminal fragment (amino acids #1–14) was observed
(Supplementary Fig. 14). Furthermore, as observed for gluconoy-
lated GH6-EGFP (Fig. 3b), a peak corresponding to unmodiﬁed
fragment #29–276 was present, while the labeled version was not
detected. This indicated that no modiﬁcation took place at this
region of the protein. Azido-functionalized N3-CH2-C(O)-GH6-
EGFP was also conjugated to a 5 kDa DBCO-PEG. SDS-PAGE
analysis revealed formation of mono-PEGylated protein with high
conversion, while di-PEGylated species were only observed as
very faint bands (Fig. 4d).
For comparison, the potential reaction between compound 18
and GSH-EGFP and GSSH6-EGFP were studied. The former
displayed negligible formation of the mono-acylated species when
treated at 35 µM with 40 equiv. of 18 in 200 mM HEPES buffer at
pH 7.5 with 10% acetonitrile for 2 days. Under the same
Table 1 Acylation of a series of peptides with GDL
Peptide Peptide sequence Acylation (%)a
2 LRFKFY-NH2 3.0 ( ± 0.7)
3 GLRFKFY-NH2 17.3 ( ± 0.7)
4 GSLRFKFY-NH2 15.7 ( ± 1.6)
5 HLRFKFY-NH2 29.8 ( ± 0.7)
6 HHHLRFKFY-NH2 64.4 ( ± 13.9)
7 GHLRFKFY-NH2 45.2 ( ± 1.7)
8 GSHLRFKFY-NH2 33.4 ( ± 1.9)
9 GHHLRFKFY-NH2 63.7 ( ± 8.6)
10 GHHHLRFKFY-NH2 81.9 ( ± 3.5)
11 AHHHLRFKFY-NH2 27.4 ( ± 4.3)
12 VHHHLRFKFY-NH2 4.3 ( ± 7.5)
aConversion of peptides 2–12 (1 mM) after treatment with 25 equiv. of GDL (1) in 200mM
HEPES buffer at pH 7.5 at room temperature for 2 h, as determined by LC–MS (UV, 215 nm).
Standard deviations are based on triplicate measurements. The His acylation tags and
compound numbers are indicated in bold
Table 2 Acylation of a series of Beltide-1 derivatives with
GDL
Peptide Acylation (%)a
Beltide-1 (13) No reaction
Ac-Beltide-1 (13Ac) No reaction
GHHH-Beltide-1 (14) ~ 73
GHHHHHH-Beltide-1 (15) 100
Ac-GHHHHHH-Beltide-1 (15Ac) No reaction
aConversion of Beltide derivatives (1 mM) after treatment with 100 equiv. of GDL (1) in 200mM
HEPES buffer at pH 7.5 at room temperature for 1 h, as determined by LC–MS (UV, 215 nm). The
His acylation tags and compound numbers are indicated in bold
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conditions, GSSH6-EGFP was modiﬁed, although with lower
selectivity than GH6-GFP. Mono-acylated protein was still
observed as the major species in ESI-MS, but also signiﬁcant
amounts of di-, and even tri-acylated species (Supplementary
Fig. 15). The low selectivity can be explained by the increase in
the distance between the N-terminal α-amine and the imidazole
side-chains of the His tag. This again conﬁrmed GHHHHHH as
an optimal N-terminal sequence for acylation. Importantly, it was
observed that neither Ac-GHHHHHH-NH2 nor imidazole
catalyzed the N-terminal acylation of GSH-EGFP by 18
(Supplementary Fig. 16).
To further evaluate the generality of the selective acylation of
the N-terminal segment, we reacted GH6-tagged MBP with 4-
methoxyphenyl ester 18. Rewardingly, under the conditions
tested mono-functionalized products were the major species
(35 μM protein, 36 equiv. 18, 4 °C). Conversion to mono-labeled
protein was determined by ESI-MS as 59% for GH6-MBP
(Fig. 4e).
To exemplify the optimization of the selective N-terminal
acylation, we reacted GH6-tagged SUMO with 4-methoxyphenyl
ester 18. Under all conditions tested mono-functionalized
products were the major species (Supplementary Table 1, Fig. 4e).
Parameters (Supplementary Table 1) such as numbers of
equivalents, temperature, and time can be used to optimize the
acylation of a protein, in this case GH6-SUMO. The multiple
additions of ester 18 took its half-life in aq. solution into
consideration. Conversion to mono-labeled GH6-SUMO was
determined by ESI-MS to be up to 80% (155 μM protein, 10+ 10
equiv. 18, 3+ 6 h, 25 °C).
In order to demonstrate the application of the method on a
biologically more relevant protein, we selected X-linked inhibitor
of apoptosis protein (XIAP) as fourth model protein. The
inhibitor of apoptosis proteins (IAPs) constitute a class of
proteins that play an essential role in the anti-apoptotic and pro-
survival signaling pathways. They are characterized by having one
or more baculovirus IAP repeats called BIR domains. These
domains of ~70 amino acids interact with different kinds of
proteins. IAPs are upregulated in various cancers and associated
with tumor growth and resistance to treatment. Therefore, IAPs
are attractive targets for antitumor drug discovery32. The site-
selective, N-terminal introduction of a ﬂuorophore or biotin
moiety in XIAP will facilitate studies aiming at the identiﬁcation
and characterization of interaction partners or inhibitors of this
class of proteins. Here, the XIAP fragment [124–240] was selected
which comprises the linker region between BIR1 and BIR2 and
the BIR2 domain, and which is known to potently inhibit
caspase-3 and -733.
A GH6-tagged version of the protein (for simplicity referred to
as GH6-BIR2) was expressed, puriﬁed by Ni2+ afﬁnity chromato-
graphy, and treated with compound 18. It was found that
treatment with 20 equiv. of compound 18 was optimal, leading to
83% conversion and 65% mono-functionalization (Supplemen-
tary Fig. 17). In order to test whether acylated GH6-BIR2 had
retained its function, a caspase-7 inhibition assay was performed
using the tetrapeptide DEVD linked to 7-amino-4-
triﬂuoromethylcoumarin (AFC) as substrate. Acylated GH6-
BIR2 was as potent in inhibiting caspase-7 as its non-modiﬁed
counterpart (Fig. 5b). Next, the possibility to ﬂuorescently label
azido-functionalized N3-CH2-C(O)-GH6-BIR2 through the Cu
(I)-catalyzed alkyne–azide cycloaddition was demonstrated, as
depicted in Fig. 5c. Furthermore, in order to evaluate whether 4-
methoxyphenyl esters could be used to directly attach larger
moieties, biotin derivative 20 (Fig. 5d) was reacted with GH6-
BIR2. Treatment with 20 equiv. of compound 20 at room
temperature for 24 h led to a ~50% conversion to mono-labeled
protein as determined by ESI-MS. Addition of an extra aliquot of
20 equiv. for 1 more day gave 80% conversion with 60% mono-
functionalization. The ability of biotinylated GH6-BIR2 to bind
streptavidin was demonstrated by western blot (Fig. 5d).
As an alternative approach, we tested whether GH6-EGFP
could be biotinylated with a 4-methoxyphenyl ester derivative of
biotin formed in situ by coupling biotin reagent 19 to compound
18 via the strain-promoted alkyne-azide cycloaddition. Approxi-
mately 45% mono-labeled protein was obtained when GH6-EGFP
was incubated with 60 equiv. of the in situ formed ester for 48 h at
4 oC (Supplementary Fig. 18).
GH6-SUMO was found to react with compound 20 to a similar
degree and with comparable selectivity as GH6-BIR2. Moreover,
biotinylated SUMO could still be processed by SUMO protease as
conﬁrmed by ESI-MS (Supplementary Fig. 19). This result
suggests that also other enzymes involved in the SUMOylation
process will still recognize the modiﬁed SUMO.
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Fig. 2 Evaluating substituted phenyl esters for His tag acylation. Phenyl esters 16–18
Table 3 Acylation of a series of Beltide-1 derivatives with 4-methoxy phenyl ester 18a
Peptide N-Terminal mono-acylated product (%) Di-acylated product (%)
Beltide-1 (13) No reaction No reaction
Ac-Beltide-1 (13-Ac) − No reaction
GHHH-Beltide-1 (14) 63 13
GHHHHHH-Beltide-1 (15) 92 8 (±1)
Ac-GHHHHHH-Beltide-1 (15Ac) − 9 (±0.5)
GHHHHHHG-Beltide-1 (15G) 97 3 (±0.5)
GHHHHHHK-Beltide-1 (15K) 87 13 (±1)
Ac-GHHHHHHK-Beltide-1 (15K-Ac) − 31 (±4)
aConversion of a series of Beltide-1 derivatives after being treated at a concentration of 1 mM with 2.5 equiv. of 4-methoxy-phenyl ester 18 at 4 °C for 24 h as determined by LC–MS (UV, 215 nm).
Standard deviations are based on duplicate measurements. Beltide-1 sequence DWLKAFYDKVAEKLKEAF, Lys underscored. The His acylation tags and compound numbers are indicated in bold
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Mechanistic studies. The Gly-Hisn sequence catalyzes the acy-
lation of the Gly Nα-amine. Fundamental studies of acyl transfer
catalysis by imidazoles have shown that the catalytic mechanism
is modulated by variations in the leaving group of the acylating
agent34–40. Strong electrophiles, such as acetic anhydride and 4-
nitrophenyl acetates, favor a nucleophilic mechanism of
imidazole catalysis involving intermediate formation of neutral
N-acyl imidazoles. In contrast, weak electrophiles, such as alkyl
esters, react by a speciﬁc base catalytic mechanism. Interestingly,
4-methoxyphenyl acetate is known to be a borderline case
between nucleophilic and speciﬁc base catalysis40. Both of the
above mentioned types of mechanisms may be envisioned in the
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present case of His tag acylation. Initial interaction with the
imidazole ring or base catalysis seems to be a requirement, since
no reaction was observed in control experiments with non-tagged
Beltide-1 (13) or its acetylated derivative 13Ac. In the case of a
hypothesized nucleophilic catalysis mechanism, the reaction
would start by formation of an N-acyl imidazole intermediate by
reaction of the ester with the imidazole side-chains of the His
residues. Then, the acyl imidazole could react with amines or
undergo hydrolysis. When the N-terminal Gly α-amine is avail-
able the reaction would occur preferentially on this amine, which
can be explained by its closer proximity and lower pKa in
comparison with amines of Lys side-chains. Alternatively, for a
speciﬁc base catalytic mechanism, the imidazoles of the His
side-chains would assist in deprotonation of the charged,
tetrahedral addition complex between the acylating agent and the
N-terminal Gly α-amine. Once again, the close proximity of the
His side-chain would further promote catalysis. In order to elu-
cidate the mechanism, we conducted a set of control experiments
where the reactivity of 4-methoxyphenyl ester 18 and acetic
anhydride (as positive control) with different imidazoles was
studied at pH 7.5. The hypothetical N-acyl derivatives of imida-
zole or Ac-GHHHHHH-NH2 were not observed in any experi-
ments involving 18, neither by UV (245 nm)40 or 1H-NMR
spectroscopy. Interestingly, nor was the N-acyl imidazole deri-
vative detectable in the presence of the more reactive 4-
nitrophenyl or phenyl esters, 16 or 17, under the applied reac-
tion conditions. In contrast, full conversion to N-acetylimidazole
was evident when acetic anhydride was used as the acylating
agent (Supplementary Fig. 20 and 21).
Furthermore, we compared hydrolysis rates of 18 in the
presence of imidazole or 2-isopropylimidazole in order to reveal
the involvement of any transiently formed N-acyl imidazole. The
steric hindrance of the 2-isopropyl group is known to affect
nucleophilic catalytic processes negatively, whereas speciﬁc base
catalytic processes of 2-isopropylimidazole are virtually unaf-
fected, as compared to imidazole34,35. The observed hydrolysis
rate of 18 with 6 mM 2-isopropylimidazole was essentially
identical to that of 6 mM imidazole or 1 mM Ac-GHHHHHH-
NH2 in HEPES buffer, pH 7.5 (Supplementary Fig. 22).
Discussion
We present a chemical method for highly selective and efﬁcient
N-terminal acylation of proteins. This method, for which we
propose the name His tag acylation, is based on a short N-
terminal peptide sequence, GHHHHHH, and is complemented
by the use of 4-methoxy phenyl esters as ﬁnely tuned acylating
agents. The method proceeds in aqueous medium, at mild tem-
perature and neutral pH. In comparison with the oxidation of an
N-terminal Ser or Thr residue or sortase-mediated N-terminal
modiﬁcation, the reaction avoids the use of harsh oxidants or
expensive enzymes. Moreover, the method, which was success-
fully applied to four unrelated proteins, is anticipated to be highly
versatile. Structural variation among proteins is known to affect
the yield of chemical N-terminal modiﬁcation strategies, such
as the transamination reaction using pyridoxal-5′-phosphate or
2-pyridinecarboxyaldehyde and the diazotransfer reaction. In
contrast to these strategies, the hydrophilic nature of our
GHHHHHH sequence will contribute to an increased accessi-
bility of the N-terminus and we anticipate that it can provide a
high yield over a wide range of proteins. Furthermore, oxidative
methods require two steps for introducing an azide. The Gly-Hisn
sequence will remain in the protein after acylation, however, the
sequence can be rather short. Other methods for N-terminal
modiﬁcation, such as sortase mediated reactions, also rely on
short peptide sequences, which remain in the ﬁnal protein
conjugate.
The optimized sequence constitutes a unique version of one of
the most widely used afﬁnity tags for protein puriﬁcation, the His
tag. In commonly used bacterial expression vectors, N-terminal
His tags are typically preceded by 3–4 amino acids. Here, we show
that by direct attachment of the HHHHHH segment to an N-
terminal Gly residue instead, a tag with dual functionality is
generated, facilitating both puriﬁcation and efﬁcient, site-speciﬁc
modiﬁcation of recombinant proteins. The non-hindered N-
terminal α-amine of Gly guarantees high conversion, while the
proximity of the His segment directs the selectivity of the reac-
tion. As demonstrated, proteins containing the GH6 tag can easily
be obtained by bacterial expression. One can rely on the excision
of the N-terminal methionine, which is known to occur during
expression when the second amino acid is small. Alternatively, in
case an N-terminal signal peptide is required, for example, for
secretion to the periplasm, this signal peptide can be removed
using the commonly employed TEV protease, thereby revealing
the needed N-terminal Gly.
Our results indicate that the mechanism behind the very high
selectivity of the His tag acylation was speciﬁc base catalysis, in
which a His side-chain assists deprotonation during the direct
acylation of the Gly α-amine. Facilitation of this type of proton
transfer is a key driving force for reaction rate enhancements in
aqueous, neutral medium41, including for enzymatic reactions.
The ester reacts preferentially with assistance from His side-chain
imidazoles since they are not protonated (pKa∼ 6.0) at the
pH of the reaction, in contrast with the N-terminal α-amine
(pKa∼ 7.6–8.0) and Lys side-chains (pKa∼ 10.5). The presence of
the additional ﬁve His residues in the His tag may serve to
modulate the basicity of the imidazole nitrogen of the catalytic
residue. A recent study has shown that the pKa values of indi-
vidual His side-chains in a His6 tag span a range from 4.8 to 7.542.
This implies that imidazoles with different acid-base properties
are to some extent organized within the His tag. A His side-chain
in an α-helix can in some cases catalyze the acylation of a ﬂanking
Lys Nε-amine in position i−3 and i+ 443. However, this requires
an engineered α-helix, whereas the present method provides a
general method for N-terminal Nα-amine acylation.
Fig. 3 Site-speciﬁc modiﬁcation of proteins with GDL. a Deconvoluted ESI-TOF spectra of the reaction of GDL with GH6-tagged EGFP, MBP, and SUMO.
The GH6-tagged proteins were reacted in 200mM HEPES buffer at pH 7.5 and room temperature. GH6-EGFP (350 µM) was treated with 200mM lactone
for 1 h. GH6-MBP (350 µM) was treated with 350mM lactone for 4 h. GH6-SUMO (42 µM) was treated with 189mM lactone for 1 h. b Detection of N-
terminal selective gluconoylation of GH6-EGFP. MS spectra of non-reacted and gluconoylated GH6-EGFP after digestion with trypsin or chymotrypsin are
depicted. MALDI-TOF spectra of the N-terminal fragment consisting of amino acids #1–14, deconvoluted ESI-TOF spectra of tryptic fragment #29–276, and
ESI-TOF spectra of chymotryptic fragment #20–29 containing Lys21 (the only Lys residue in the ﬁrst 28 amino acids of the protein) are depicted. The peak
at 1595.219 Da detected in the MALDI-TOF spectrum of the gluconoylated protein was attributed to the partial reversibility of this reaction, which was also
observed for peptide 15 (Supplementary Fig. 9 and 10). c Deconvoluted ESI-TOF spectra of the reaction of three EGFP variants with GDL. The proteins were
reacted at a concentration of 35 µMwith 200mM GDL for 1 h in 200mM HEPES buffer at pH 7.5 and room temperature. The degrees of conversion, based
on the deconvoluted MS data, were 92%, 60%, and 66% for GH6-EGFP, GSSH6-EGFP, and GSH-EGFP, respectively. Unmodiﬁed proteins are labeled SM,
and species corresponding to the correct product mass are labeled P
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4-Methoxyphenyl esters, such as azido reagent 18 and biotin
reagent 20, were found to provide the best performance in terms
of reactivity vs selectivity. These reagents are easy to prepare and
allow for the one-step introduction of an N-terminal function-
ality. As demonstrated, azido acetyl moieties can be smoothly
introduced and used for subsequent azide–alkyne couplings.
Functional moieties, such as a biotin, can be incorporated in a
single step as well. Importantly, the reactivity of the acylating
agent and the catalytic properties of the His tag are optimized for
selective reaction at the N-terminus. The selectivity for N-
terminal acylation of proteins with our His acylation tag should
be seen in view of the number of competing Lys residues. EGFP
has 21 Lys residues, MBP has 35, SUMO 9 and Bir2 3. For
example, a 9:1 ratio for acylation of the α-amine in EGFP over
any of the ε-amines would correspond to an effective
189:1 selectivity for the α-amine over each of the ε-amines.
The focus of our study was to develop a general method for N-
terminal chemical modiﬁcation of proteins for use in chemical
biology and in development of biopharmaceuticals. The chemical
modiﬁcation of the His tag with acetic acid derivatives is stable, in
contrast to some other methods. The fact that ester 18 could
introduce with high selectivity an azido moiety at 4 °C is a par-
ticularly attractive feature. We anticipate that the method also has
the potential to be used for selective labeling of proteins in a cell
lysate or even in cells for bioimaging.
Methods
Materials. Synthesis and puriﬁcation: N,N′-dicyclohexylcarbodiimide (DCC),
dichloromethane (DCM), 4-(dimethylamino)pyridine (DMAP), heptane, ethyl
acetate (EtOAc), N,N-dimethylformamide (DMF), benzyl bromoacetate, magne-
sium sulfate (MgSO4), palladium hydroxide on carbon (Pd(OH)2/C), Celite, trie-
thylsilane (TES), diethyl ether (Et2O), acetonitrile (MeCN), Sodium carbonate
(Na2CO3), and gluconolactone (GDL) were purchased from Sigma-Aldrich
(Brøndby, Denmark). N-[(1H-azabenzotriazol-1-yl)(dimethylamino)methylene]-
N-methylmethanaminium hexaﬂuorophosphate N-oxide (HATU), N-[(1H-ben-
zotriazol-1-yl)(dimethylamino)methylene]-N-methylmethanaminium hexa-
ﬂuorophosphate N-oxide (HBTU), and 1-Hydroxy-7-azabenzotriazol (HOAt) were
purchased from GL Biochem Ltd. (Shanghai, China). N,N
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Fig. 4 Functionalization of proteins with azides, biotin and PEG. a Schematic representation of the two-step biotinylation of GH6-EGFP. Reaction conditions
for the biotinylation step: 100 µM azido-functionalized N3-CH2-C(O)-GH6-EGFP with 1.5 equiv. of 19 in 100mM phosphate buffer with 1% acetonitrile at
pH 7.5 and room temperature for 1 h. b Deconvoluted ESI-TOF spectrum of the reaction of GH6-EGFP with phenyl ester 18. c Deconvoluted ESI-TOF
spectrum of the reaction of azido-functionalized GH6-EGFP with DBCO-PEG4-biotin 19. d SDS-PAGE analysis of the two-step PEGylation of GH6-EGFP.
Lane 1: protein marker, lane 2: GH6-EGFP, lane 3: azido-functionalized GH6-EGFP, lane 4: reaction of azido-functionalized GH6-EGFP with 5 kDa DBCO-PEG.
Reaction conditions for the PEGylation step: 100 µM azido-functionalized N3-CH2-C(O)-GH6-EGFP with 2.5 equiv. of 5 kDa DBCO-PEG in 100mM
phosphate buffer at pH 7.5 and room temperature for 3 h. e Deconvoluted ESI-TOF spectra of the reactions of GH6-SUMO (Supplementary Table 1, Entry
8) and GH6-MBP with phenyl ester 18. Unmodiﬁed proteins are labeled SM, and species corresponding to the product masses are labeled P1 and P2 (the
number indicating the number of azides or biotins, respectively)
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′-diisopropylcarbodiimide (DIC), 1-methylimidazole (MeIm), N-methyl-2-pyrro-
lidone (NMP), N,N-dimethylformamide (DMF), N,N-diisopropylethylamine
(DIPEA), piperidine, triﬂuoroacetic acid (TFA), and all Fmoc-protected amino
acids were purchased from Iris Biotech GmbH (Marktredwitz, Germany). Sodium
acetate (NaOAc) was acquired from Merck Millipore (Darmstadt, Germany). All
peptide syntheses were carried out on Tenta Gel S Rink Amide (loading 0.22 mmol
g−1; Rapp Polymere GmbH). Amino acids were Fmoc protected at Nα-amino
groups; side-chain protecting groups were tert-butyl (Ser, Tyr, and Glu), trityl (Trt,
for Gln) and tert-butyloxycarbonyl (Boc, for Lys). Water was puriﬁed using an
Ultra Clear Water System (Siemens) set at 0.055 µS cm−1.
Synthesis of phenyl 2-azidoacetates 16–18. The phenol (200 mg) was dissolved
in CH2Cl2 (5 mL), and 4-dimethylaminopyridine (0.1 equiv.) was added. 2-
Azidoacetic acid (1.2 equiv.) was dissolved in CH2Cl2 (5 mL) with N,N’-diisopro-
pylcarbodiimide (1.2 equiv.) and stirred for 15 min, before it was added carefully to
the phenol solution. The reaction mixture was stirred under N2. After 2 h, addi-
tional 2-azidoacetic acid (1.2 equiv.) and N,N’-diisopropylcarbodiimide (0.6 equiv.)
were added to the reaction mixture, and stirring was continued for 2 h. Then, the
reaction mixture was concentrated by rotary evaporation, and the crude product
was puriﬁed using an Isolera One instrument from Biotage™ equipped with a 25 g
KP-Sil column. The product was eluted with CH2Cl2, and fractions containing the
pure product were combined and concentrated by rotary evaporation. The product
was dried in vacuo.
Analysis of 4-nitrophenyl 2-azidoacetate (16). Colorless oil, 294 mg (92%). 1H
NMR (300MHz, CDCl3): δ 8.36–8.19 (m, 2H, 2 × H-Ar), 7.45–7.27 (m, 2H, 2 × H-
Ar), 4.19 (s, 2H, CH2). 13C NMR (75MHz, CDCl3) δ 166.18 (s, C=O), 154.67 (C-
Ar), 145.86 (C-Ar), 125.48 (2 × C-Ar), 122.27 (2 × C-Ar), 50.52 (CH2). HR-MS (Q-
TOF): m/z calcd. for chemical formula C8H6N4O4: 222.0389; found: [M+Na]+
245.0243 (Supplementary Fig. 23).
Analysis of phenyl 2-azidoacetate (17). Colorless oil, 294 mg (78%). 1H NMR
(300MHz, CDCl3), δ 7.49–7.38 (m, 2H, 2 × H-Ar), 7.34–7.25 (m, 1H, H-Ar),
7.21–7.13 (m, 2H, 2 × H-Ar), 4.15 (s, 2H, CH2). 13C NMR (75MHz, CDCl3) δ
166.95 (C=O), 150.23 (C-Ar), 129.71 (2 × C-Ar), 126.50 (C-Ar), 121.28 (2 × C-
Ar), 50.54 (CH2). HR-MS (Q-TOF): m/z calcd. for chemical formula C8H7N3O2:
177.0538; found: [M+Na]+ 200.0426 (Supplementary Fig. 24).
Analysis of 4-methoxyphenyl 2-azidoacetate (18). Colorless oil, 316 mg (95%).
1H NMR (300MHz, CDCl3), δ 7.12–7.02 (m, 2H, 2 × H-Ar), 6.97–6.87 (m, 2H, 2 ×
H-Ar), 4.12 (s, 2H, CH2), 3.82 (s, 3H, CH3). 13C NMR (75MHz, CDCl3) δ 167.29
(C=O), 157.73 (C-Ar), 143.69 (C-Ar), 122.05 (2 × C-Ar), 114.67 (2 × C-Ar), 55.68
(CH3), 50.49 (CH2). HR-MS (Q-TOF): m/z calcd. for chemical formula C9H9N3O3:
207.0644; found: [M+Na]+ 230.0503 (Supplementary Fig. 25).
Reagent 18 has the composition C9H9O3N3, which gives a (carbon+ oxygen
per azide nitrogen) ratio of 4. It can thus be considered relatively stable.
Gram-scale synthesis of 4-methoxyphenyl 2-azidoacetate 18. 4-
Methoxyphenol (1.03 g, 8.3 mmol) and 4-dimethylaminopyridine (100 mg,
0.8 mmol) were dissolved in CH2Cl2 (50 mL) under stirring. 2-Azidoacetic acid
(1.01 g, 10.0 mmol) was added. Then, N,N’-diisopropylcarbodiimide (1.57 mL, 10.0
mmol) was added dropwise over a period of 10 min. The reaction mixture turned
yellow to brown over 30 min. Stirring was continued for 1.5 h. Then, Celite (10 g)
was added to the reaction mixture, and the solvent was removed by rotary
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Fig. 5 Functionalization of GH6-BIR2 with an azide, a ﬂuorophore and biotin. a 3D structure of XIAP(124–240) with the linker region known to interact with
caspase-3 and -7 depicted on the left and the BIR2 domain on the right. The reaction scheme of the inhibition assay is shown as well. The tetrapeptide
DEVD is hydrolyzed by caspase-7 between the second aspartic acid and the AFC reporter group. AFC= 7-amino-4-triﬂuoromethylcoumarin. b Kinetic
curves of the hydrolysis of Ac-DEVD-AFC by caspase-7, without inhibition (ﬁlled triangles) or when inhibited by unmodiﬁed (horizontal lines) or acylated
(open circles) GH6-BIR2. The substrate only (crosses) was included as reference as well. c Two-step ﬂuorescent labeling of GH6-BIR2 through acylation
with 4-methoxyphenyl ester 18 followed by Cu(I)-catalyzed conjugation of alkyne cyanine dye 718, visualized by SDS-PAGE analysis. A ﬂuorescence image
and an image of the Coomassie-stained version of the same gel are shown. Lane 1: GH6-BIR2 treated with alkyne cyanine dye 718 and Cu(I) (negative
control), lane 2: azido-functionalized GH6-BIR2 treated with alkyne cyanine dye 718 and Cu(I). d Direct biotinylation of GH6-BIR2 with 4-methoxyphenyl
ester 20, visualized by Western blot analysis. Binding of streptavidin to biotinylated GH6-BIR2 (lane 2) was detected by incubating the blot with HRP-SAv,
a conjugate of streptavidin and horseradish peroxidase (HRP), followed by the addition of a chemoluminescent substrate of HRP. Unmodiﬁed GH6-BIR2
was loaded in lane 1 as negative control
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evaporation. The resulting brown Celite adsorbate was loaded on top of a pre-
conditioned (ethyl acetate/heptane 1:39) column for vacuum liquid chromato-
graphy (H ×D= 7 × 5 cm; silica gel 60 (0.015–0.040 mm)), and the product was
eluted using a gradient of ethyl acetate/heptane (1:39→1:3). Fractions containing
the pure product were combined and concentrated by rotary evaporation. The
product was dried in vacuo to yield 1.63 g (95%) of 18 as a colorless oil.
Synthesis of biotin OEG 4-methoxyphenyl ester 20. A solution of 8-(9-ﬂuor-
enylmethyloxycarbonylamino)-3,6-dioxaoctanoic acid (1.93 g, 5 mmol, 5 equiv.) in
dry DCM 4mL) was added to 2-chlorotrityl chloride polystyrene resin (1 g,
1 mmol g−1, 100–200 mesh, 1% DVB), and the reaction mixture was agitated for
16 h. The resin was washed with DCM (5 × 4mL) and DMF (5 × 4 mL), and the
Fmoc group was removed by treatment with 20% piperidine in DMF (4 mL) for 5
min., followed by 20% piperidine in DMF (4 mL) for 15 min. The resin was then
washed with DMF (5 × 4mL), and DCM (5 × 4mL), followed by DMF (5 × 4mL).
Biotin (150 mg, 0.6 mmol) was preactivated with HATU (190 mg, 0.5 mmol),
HOAt (75 mg, 0.55 mmol), and DIEA (150 μL, 0.85 mmol) in DMF (4 mL) for 5
min, and then added to the above resin (0.5 mmol). The reaction mixture was
agitated for 2 h, and the resin was subsequently washed with DMF (5 × 4mL),
followed by DCM (5 × 4mL). The resin was treated with TFA containing 5% water
and 0.5% triethylsilane for 1 h. The cleaved biotin OEG acid was puriﬁed by RP-
HPLC (on a Dionex Ultimate 3000 system) using a preparative C18 column
(Phenomenex Gemini, 110 Å 5 µm C18 particles, 21 × 100 mm): Solvent A, water
containing 0.1% TFA, and solvent B, acetonitrile containing 0.1% TFA, were used
with gradient elution (0–5 min: 5–100% 5–32 min) at a ﬂow rate of 15 mLmin−1.
This material (55 mg, 0.14 mmol) was dissolved in dry DCM (5 mL), to which was
added 4-methoxyphenol (20 mg, 0.16 mmol), 4-dimethylaminopyridine (2 mg,
0.1 mmol), followed by DIC (20 mg, 0.16 mmol). The reaction mixture was stirred
for 16 h, after which it was concentrated by rotary evaporation. The product was
puriﬁed by RP-HPLC (on a Dionex Ultimate 3000 system) using a preparative C18
column (Phenomenex Gemini, 110 Å 5 µm C18 particles, 21 × 100 mm): Solvent A,
water containing 0.1% TFA, and solvent B, acetonitrile containing 0.1% TFA, were
used with gradient elution (0–5 min: 5–100% 5–32 min) at a ﬂow rate of 15 mL
min−1. The provided the product, [2-[2-(D-biotinyl-amino)ethoxy]ethoxy]acetic
acid 4-methoxyphenyl ester 20 (25 mg, 36%), as a white solid. 1H NMR (500 MHz,
CD3CN), δ 7.08–7.02 (m, 2H, 2 × H-Ar), 6.97–6.92 (m, 2H, 2 × H-Ar), 6.50 (br s,
1H, NH), 5.15 (br s, 1H, NH), 4.95 (br s, 1H, NH), 4.40 (ddt, J= 1.0 and 5.2 and
7.6 Hz, 1H, biotin CH), 4.37 (s, 2H, CH2CO), 4.22 (ddd, J= 2.0 and 4.5 and 7.6 Hz,
1H, biotin CH), 3.79 (s, 3H, OMe), 3.74–3.71 (m, 2H, CH2O), 3.63–3.60 (m, 2H,
CH2O), 3.49 (t, J= 5.4 Hz, 2 H, CH2O), 3.30 (dd, J= 5.6 and 11.3 Hz, 2H, CH2N),
3.17–3.11 (m, 1H, biotin CHS), 2.88 (dd, J= 4.8 and 12.7 Hz, 1H, biotin CH2S),
2.63 (d, J= 12.7 Hz, 1H, CH2S), 2.11 (t, partly overlapped by HDO, J= 7.4 Hz, 2H,
biotin CH2CO), 1.70–1.48 (m, 4H, biotin CH2), 1.40–1.32 (m, 2H, biotin CH2). 13C
NMR (125MHz, CD3CN), δ 173.8, 170.8, 163.7, 158.5, 144.8, 123.5, 115.5, 71.6,
70.9, 70.4, 69.1, 62.3, 60.8, 56.4, 56.3, 41.2, 39.8, 36.3, 29.0, 28.9, 26.4. HR-MS (Q-
TOF): m/z calcd. for chemical formula C23H33N3O7S: 495.2039; found: [M+Na]+
518.1998; [M+H]+ 496.2124 (Supplementary Fig. 26 and 27).
Synthesis of peptides. The Beltide-1 peptides were assembled by Fmoc solid-
phase peptide synthesis on a Biotage® Initiator+AlstraTM microwave peptide
synthesizer. The short peptides were synthesized on a parallel automated peptide
synthesizer (Biotage® SYRO 2). The syntheses were carried out on Tenta Gel R
Rink Amide resin (loading 0.22 mmol g−1).
In the synthesis of the short peptides (Table 1), Nα-Fmoc deprotection was
performed at room temperature in two stages by treating the resin with piperidine/
DMF (1:4) for 3 min followed by piperidine/DMF (1:3) for 15 min. The resin was
then washed with NMP (3×), DCM (1×), and NMP (3×). Peptide couplings were
performed using 5.2 equiv. of Fmoc-AA in DMF (0.5 M), 5.2 equiv. of HOAt in
DMF (0.5 M), 5.0 equiv. of HBTU in DMF (0.6 M), and 9.36 equiv. of DIEA in
NMP (2M). The coupling time was 120 min at RT, after which the resin was
washed with NMP (3×), DCM (1×), and NMP (3×).
In the synthesis of Beltide-1 peptides (Tables 2 and 3), Nα-Fmoc deprotections
were performed at room temperature in two stages by treating the resin with
piperidine/DMF (1:4) for 3 min followed by piperidine/DMF (1:3) for 15 min. The
resin was then washed with NMP (3×). DCM (1×). DMF (1×). Peptide couplings
were performed using 5.2 equiv. of Fmoc-AA in DMF (0.5 M), 5.2 equiv. of HOAt
in DMF (0.5 M), 5.0 equiv. of HBTU in DMF (0.6 M) and 9.36 equiv. of DIEA in
NMP (2M). The coupling time was 10 min at 75 °C, after which the resin was
washed with NMP (4×).
N-acetylated peptides were obtained by on-resin acetylation with Ac2O in DMF.
After the synthesis was completed the resin was washed with DCM (6×) and
thoroughly dried. The peptides were cleaved from the resin with TFA-H2O-TES
(95:3:2) for 5 min. and then for 2 h. The peptides were precipitated with cold
diethyl ether to yield the crude products.
Puriﬁcation of peptides. The peptides were puriﬁed by RP-HPLC (on a Dionex
Ultimate 3000 system) with preparative C18 column (Phenomenex Gemini, 110 Å
5 µm C18 particles, 21 × 100 mm). For the short peptides (Table 1) solvent A, water
containing 0.1% TFA; solvent B, acetonitrile containing 0.1% TFA, were used with
gradient elution (0–5 min: 5–40% 5–32 min) at a ﬂow rate of 15 mLmin−1, while
for the Beltide containing peptides (Tables 2–3) solvent A, water containing 0.1%
TFA, and solvent B, acetonitrile containing 0.1% TFA, were used with gradient
elution (0–5 min: 5–100% 5–32 min) at a ﬂow rate of 15 mLmin−1.
Analysis of peptides and proteins. Analyses of peptides were performed by
UHPLC-MS on a RSLC Dionex Ultimate 3000 (Thermo) coupled to a QTOF
Impact HD (Bruker) on a kinetex 2.6 µm EVO 100 Å C18 column (50 × 2.1 mm,
Phenomenex) which were used for the peptides and Aeris 3.6 µm widepore C4
column (50 × 2.1 mm, Phenomenex) for the proteins. The following solvent system
was used at a ﬂow rate of 0.5 mL min-1: solvent A, water containing 0.1% formic
acid; solvent B, acetonitrile containing 0.1% formic acid. The column was eluted
using a linear gradient from 5 to 100% of solvent B. Some short peptides (Table 1)
were analyzed on analytical HPLC (Dionex Ultimate 3000) instrument with an
analytical C18 column (Phenomenex Gemini NX 110 Å, 5 µm, C18 particles,
4.60 × 50 mm) coupled to a ESI-MS (MSQ Plus Mass Spectrometer, Thermo) using
a linear gradient ﬂow of water-acetonitrile containing 0.1% formic acid (Supple-
mentary Tables 2 and 3). MALDI-TOF MS spectra were recorded on a Bruker
autoﬂex™ speed MALDI-TOF instrument.
As for the protein modiﬁcation reactions, conversions were based on relative
abundance values calculated from deconvoluted MS data. Given the large number
of positive charges that the proteins pick up when analyzed by ESI-MS, the effect of
the loss of a single positive charge upon acylation of the N-terminus is expected to
be negligible. EGFP picks up 20–40 charges, MBP 20 to >50, SUMO 8–20, and
BIR-2 10–24.
Expression of proteins. The expression plasmid for GH6-EGFP was generated
from the pET15b-EGFP plasmid encoding GSSH6-EGFP44. The two N-terminal
serine codons were deleted by PCR using the following primers: 5′-
TTTGTTTAACTTTAAGAAGGAGATATATACCATGGGCCATCATCATC-3′
and 5′-CTAGTTATTGCTCAGCGGT-3′. The insert, treated with NcoI and
BamHI (New England Biolabs), was ligated in the pET15 vector, digested with the
same restriction enzymes. DH5α cells (Invitrogen) were used for cloning. The
plasmid was sequenced using the T7 forward primer (5′-TAATACGACTCAC
TATAGGG-3′, Euroﬁns). E. coli BL21[DE3] cells were transformed with plasmid
encoding GH6-tagged EGFP or GSSH6-tagged EGFP. Cultures were grown in
250 mL LB medium with 100 μg mL-1 ampicillin and protein expression was
induced with 1 mM IPTG for 4 h at 37 °C. Cells were harvested and resuspended in
15 mL of 50 mM NaH2PO4, 300 mM NaCl at pH 8. Lysozyme was added to a ﬁnal
concentration of 1 mgmL−1 and lysis was allowed to take place by incubation for
30 min on ice. The lysate was sonicated and centrifuged at 18,000 × g at 4 oC for
30 min. The supernatant was incubated with 1 mL of Ni-NTA resin for 20 min
under gentle stirring. The resin was loaded into a gravity column, washed with 2 ×
10 mL of lysis buffer (50 mM NaH2PO4, 300 mM NaCl at pH 8) and 10 mL of wash
buffer (50 mM NaH2PO4, 300 mM NaCl, 2 mM imidazole at pH 8), and eluted in 3
mL elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole at pH 8).
An additional puriﬁcation step was performed on an ÄKTA™ pure system equipped
with a HiLoad 16/600 Superdex 75 pg column (GE Healthcare). Fractions con-
taining the protein (as conﬁrmed by SDS-PAGE analysis) were pooled and con-
centrated using a centrifugal ﬁlter unit (Amicon, Ultra-15, MWCO 10 kDa).
The protein concentration was determined by measuring absorbance at 490 nm
on a Nanodrop 2000 (Thermo Scientiﬁc) using an extinction coefﬁcient of
55,000 M−1 cm−1. The protein (4.4 mgmL−1) was frozen in aliquots in liquid
nitrogen and stored at −20 °C.
GSH-tagged EGFP was produced by incubation of GSSH6-tagged EGFP
(100 µg) with thrombin (0.05 U, Thrombin cleavage capture kit, Novagen) for 16 h
at room temperature. Efﬁcient removal of the N-terminal peptide
GSSHHHHHHSSGLVPR was conﬁrmed by MALDI-TOF analysis. Biotinylated
thrombin was removed by incubation with streptavidin agarose, according to the
manufacturer’s protocol.
The DNA coding for OneStrep-TEV-Gly-His-Sumo (smt3_Q12306) was
ordered codon-optimized for E. coli from Geneart. Plasmid pNIC28-
StrepTEVGlyHisSumo was created by digestion with NdeI and BamHI and ligation
into the corresponding sites of plasmid pNIC28-Bsa4. After transformation of the
plasmid into E. coli BL21[DE3], cells were cultured in 500 mL 2xYT medium
containing 50 μg mL−1 kanamycin at 37 °C until mid-exponential phase, at which
time expression was induced with 1 mM IPTG for 16 h at 18 °C. After harvesting,
cells were lysed by three passes through an EmulsiFlex-C5 homogenizer (Avestin)
at 10–15k psi and any debris and unbroken cells were removed by centrifuging at
18,000 × g at 4 °C for 15 min. For protein puriﬁcation, the supernatant was loaded
onto a StrepTrap HP column (GE Healthcare, Piscataway, NJ, USA) on an Äkta™
pure system. Puriﬁcation was performed as per the speciﬁcations of the
manufacturer. Cleavage of the OneStrep tag was performed with 1:100 (w/w)
recombinant His-tagged TEV protease (produced in-house) overnight at 4 °C. TEV
cleavage was assessed by SDS-PAGE and was found to be complete. TEV protease
and SUMO protein with an N-terminal glycine residue followed by a His6 tag were
subsequently separated by size exclusion chromatography using a HiLoad 16/600
Superdex 75 pg column (GE Healthcare).
Competent E. coli BL21[DE3] cells were transfected with the pET28a plasmid
containing the MBP coding sequence (malE_P0AEX9). They were grown in LB
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medium at 37 °C with kanamycin and induced with 1 mM IPTG for 3 h. The cells
were harvested by centrifugation at 4000 × g for 10 min and resuspended in lysis
buffer containing 40 mM Tris/HCl pH 8.5, 400 mM NaCl and 20 mM imidazole.
The cells where lysed by two cycles of a French press at 35k psi. Cell debris was
spun down for one hour at 18,000 × g. The supernatant was incubated with Ni-
NTA resin for one hour under gentle stirring. The resin was loaded into a gravity
column, washed in wash buffer containing 40 mM Tris/HCl pH 8.5, 1 M NaCl and
20 mM imidazole and eluted in elution buffer containing 40 mM Tris/HCl pH
8.5, 200 mM NaCl and 500 mM imidazole. DTT was added to a ﬁnal concentration
of 1 mM and cleavage of the N-terminal tag was performed with 1:100 (w/w) TEV
protease. The cleavage reaction was left at 20 °C overnight. The protein was
simultaneously dialyzed against a large reservoir of buffer containing 50 mM Tris/
HCl pH 8.5. Minor precipitate was removed by centrifugation and the protein was
loaded onto a 15 mL anion exchange column (Q-sepharose High Performance, GE
Healthcare) equilibrated in buffer containing 50 mM Tris/HCl pH 8.5. A linear
gradient of 5 column volumes using a buffer containing 50 mM Tris/HCl pH 8.5
and 1M NaCl was used to elute the protein. Peak fractions were collected and
dialyzed overnight at 4 °C into a buffer containing 200 mM HEPES pH 7.5 and
20 mM NaCl. Peak fractions were then concentrated, aliquoted, ﬂash frozen, and
stored at −80 °C until further use.
A gene fragment coding for residues 124–240 of human X-linked inhibitor of
apoptosis protein (xiap_P98170) was ordered codon-optimized for E. coli from
Euroﬁns. Plasmid pET15b-GH6-XIAP[124-240] was created by digestion with
NcoI and BamHI and ligation into the corresponding sites of plasmid pET15b. E.
coli BL21[DE3] cells were transformed with the respective plasmid. A culture was
grown in 750 mL LB medium with 100 μg mL−1 ampicillin and protein expression
was induced with 1 mM IPTG for 3.5 h at 37 °C. Cells were harvested and
resuspended in 50 mM NaH2PO4, 300 mM NaCl at pH 8, supplemented with
cOmplete™, EDTA-free protease inhibitor cocktail (Roche). Lysozyme was added to
a ﬁnal concentration of 1 mgmL−1 and lysis was allowed to take place by
incubation for 1 h on ice. The lysate was sonicated and centrifuged at 12,000 × g at
4 oC for 45 min. Imidazole and 2-mercaptoethanol were added to the cleared lysate
to a ﬁnal concentration of 20 mM. The protein was puriﬁed over a HisTrap column
(GE Healthcare), followed by a size-exclusion chromatography (SEC) step over a
Superdex75 Increase 10/300 GL column (GE Healthcare) using 50 mM NaH2PO4,
150 mM NaCl at pH 7.5 as eluent. Purity was conﬁrmed by SDS-PAGE. The
fraction of endogenously gluconoylated protein (~25%) was efﬁciently removed by
incubation of the puriﬁed protein at 37 °C for 1 day.
Gluconoylation of model peptides. A 2 mM solution of the corresponding pep-
tide in 200 mM HEPES buffer at pH 7.5 was mixed with equal volume of 50 mM
solution of GDL in 200 mM HEPES buffer at pH 7.5 and the resulting solution was
incubated at room temperature. The progress of the reactions was monitored by
LC–MS (Table 1).
Gluconoylation of Beltides 13–15. An aliquot of 100 µL of a freshly prepared 1 M
solution of GDL in water was added to a 1 mL of 1 mM solution of Beltide deri-
vative in 200 mM HEPES buffer at pH 7.5 at room temperature. The resulting
solution was incubated at that temperature and the progress of the reaction was
monitored by LC–MS (Table 2).
Reaction of Beltides 13–15 with 4-methoxyphenyl ester 18. An aliquot of
100 µL of 25 mM solution of 4-methoxyphenyl 2-azidoacetate 18 in acetonitrile
was added to a 1 mL of 1 mM solution of Beltide derivative in 200 mM HEPES
buffer at pH 7.5 at 4 oC. The resulting solution (2.5 mM in 18) was incubated at
that temperature and the progress of the reaction was monitored by LC–MS
(Table 3 and Supplementary Table 3).
Gluconoylation of proteins. An aliquot of 10 µL of a freshly prepared 2M solution
of GDL in water was added to 100 µL of 35 µM solution of the corresponding EGFP
variant in 200 mM HEPES buffer at pH 7.5 at room temperature. The resulting
solution was incubated at that temperature and the progress of the reaction was
monitored by LC–MS.
An aliquot of 10 µL of a freshly prepared 3.5 M solution of GDL in water was
added to 100 µL of 350 µM solution of GH6-MBP in 200 mM HEPES buffer at pH
7.5 at room temperature. The resulting solution was incubated at that temperature
and the progress of the reaction was monitored by LC–MS.
An aliquot of 10 µL of a freshly prepared 1.89 M solution of GDL in water was
added to 100 µL of 42 µM solution of GH6-SUMO in 200 mM HEPES buffer at pH
7.5 at room temperature. The resulting solution was incubated at that temperature
and the progress of the reaction was monitored by LC–MS.
Reaction of GH6 proteins with 4-methoxyphenyl ester 18. An aliquot of 23 µL
of a 14 mM solution of 4-methoxyphenyl 2-azidoacetate 18 in acetonitrile was
added to 80 µL of a 35 µM solution of the GH6-GFP in 200 mM HEPES buffer at
pH 7.5 at 4 oC. The resulting solution was incubated at that temperature and the
progress of the reaction was monitored by LC–MS.
An aliquot of 2 µL of a 14M solution of 4-methoxyphenyl 2-azidoacetate 18 in
acetonitrile was added to 20 µL of a 35 µM solution of the GSH-EGFP and GSSH6-
EGFP variants in 200 mM HEPES buffer at pH 7.5 at 4 oC. The resulting solution
was incubated at that temperature and the progress of the reaction was monitored
by LC–MS.
An aliquot of 8 µL of a 14 mM solution of 4-methoxyphenyl 2-azidoacetate 18
in acetonitrile was added to 80 µL of a 35 µM solution of GH6-MBP in 200 mM
HEPES buffer at pH 7.5 at 4 oC. The resulting solution was incubated at that
temperature and the progress of the reaction was monitored by LC–MS.
An aliquot of 8 µL of a 31 mM solution of 4-methoxyphenyl 2-azidoacetate 18
in acetonitrile was added to 80 µL of a 170 µM solution of GH6-SUMO in 200 mM
HEPES buffer at pH 7.5 at 4 oC. The resulting solution was incubated at that
temperature for a period of 16 h, and the progress of the reaction was monitored by
LC–MS. Different reaction conditions were investigated in order to optimize the
conversion and lower side reactions; the 4-methoxyphenyl 2-azidoacetate 18
concentration (from 2.5 to 40 equiv.), the temperature (4 or 25 °C), and the
reaction time (1–36 h) were varied (Supplementary Table 1).
An aliquot of 2 µL of a stock solution of 4-methoxyphenyl 2-azidoacetate 18 in
acetonitrile was added to 30 µL of a 40 µM solution of GH6-Bir2 in 50 mM
NaH2PO4, 150 mM NaCl at pH 7.5 at 4 oC. (NB: Here, the acylation reaction was
performed in the buffer used during the ﬁnal puriﬁcation step of GH6-BIR2. It
underscores that the reaction is not limited to HEPES buffer and that it can be
performed in other (more common) buffers, too.) The concentration of 18 in the
stock solution was adjusted according to the number of equiv. that was to be
assessed (ranging from 7.5 to 40 equiv.). The reactions were incubated at 4 oC for
16–20 h and analyzed by LC–MS.
Two-step biotinylation and PEGylation of GH6-EGFP. An aliquot of 23 µL of a
14 mM solution of 4-methoxyphenyl 2-azidoacetate 18 in acetonitrile was added to
80 µL of a 35 µM solution of GH6-EGFP variant in 200 mM HEPES buffer at pH
7.5 at 4 oC. The resulting solution was incubated at that temperature and the
progress of the reaction was monitored by LC–MS. After 3 days excess of reagent
and/or hydrolysis products were removed by repetitive (5×) centrifugal ﬁltration
(Millipore Amicon Centriplus 3 kDa cut-off) and redissolution (10× dilution) steps
using 100 mM sodium phosphate buffer at pH 7.5 as washing solution to obtain
80 µL of 100 µM solution of azido-functionalized N3-CH2-C(O)-GH6-EGFP in
100 mM sodium phosphate buffer at pH 7.5 that was used for subsequent con-
jugation with DBCO-PEG4-Biotin 19 and 5 kDa DBCO-PEG.
An aliquot of 1 µL of a 6 mM solution of DBCO-PEG4-Biotin 19 in CH3CN/
H2O 1:1 was added to 40 µL of a 100 µM azido-functionalized N3-CH2-C(O)-GH6-
EGFP in 100 mM sodium phosphate buffer at pH 7.5 and room temperature. The
resulting solution was incubated at that temperature and the progress of the
reaction was followed by LC–MS.
An aliquot of 1 µL of a 2.5 mM solution of 5 kDa DBCO-PEG in water was
added to 20 µL of a 100 µM azido-functionalized N3-CH2-C(O)-GH6-EGFP in
100 mM sodium phosphate buffer at pH 7.5 and room temperature. The resulting
solution was incubated at that temperature and the progress of the reaction was
followed by LC–MS.
Fluorescent labeling of GH6-BIR2. Thirty equivalent of alkyne cyanine 718
(1.5 µL of a 10 mM stock solution in DMSO, Sigma Aldrich) were added to 10 µL of
40 µM GH6-BIR2 pre-modiﬁed with 18. An aliquot of 1.2 µL of a freshly prepared
mixture of 2.5 mM CuSO4, 12.5 mM Tris(3-hydroxy propyltriazolylmethyl)amine
(THPTA) and 37.5 mM sodium ascorbate was added to catalyze the cycloaddition.
As a negative control, non-modiﬁed GH6-BIR2 was treated with alkyne ﬂuor-
ophore and Cu(I) catalyst as well. The reactions were incubated at room tem-
perature overnight while kept in the dark, and analyzed by SDS-PAGE. Fluorescent
bands were detected on a Typhoon 7000 FLA laser scanner (λex 635 nm, λem
670 nm, PMT at 1000). Afterwards, the gel was stained with Coomassie Brilliant
Blue R250.
Caspase-7 inhibition assay. Caspase-7 (500 nM) was pre-activated by incubation
for 15 min at 37 oC in assay buffer (20 mM PIPES (pH 7.4), 100 mM NaCl, 1 mM
EDTA, 0.1% CHAPS, 10% sucrose and 10 mM DTT). Then, BIR2 was added in
equimolar amount to the activated enzyme, followed by an additional incubation
step for 15 min at 37 oC. The enzyme/inhibitor solution (50 µL) was mixed with a
pre-heated solution of Ac-DEVD-AFC (50 µL, 200 µM in assay buffer, 2% DMSO),
resulting in ﬁnal concentrations of 100 µM substrate and 250 nM caspase-7/BIR2.
The formation of ﬂuorescent product was followed at 37 oC for 1 h using a
SpectraMax i3x plate reader (λex= 405 nm, λem= 500 nm). Measurements were
performed in duplicate.
Biotinylation of GH6-BIR2. Twenty equivalent of compound 20 (4 μL of a 10 mM
stock solution in 1:1 acetonitrile:water) were added to 50 μL of 40 μMGH6-BIR2 in
50 mM NaH2PO4, 150 mM NaCl (pH 7.5). The reaction was incubated at 4 °C for
24 h and analyzed by LC–MS and western blot.
Trypsin and chymotrypsin digestion. Excess of GDL, phenyl ester 18 or DBCO-
PEG4-biotin were removed by repeated (ﬁve times) centrifugal ﬁltration using a
0.5-mL Amicon Ultra centrifugal ﬁlter (10 MCWO). Trypsin (sequencing-grade,
modiﬁed, Sigma-Aldrich) digestions were performed overnight at 37 °C in 0.1 M
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NH4HCO3 (pH 8). Chymotrypsin (sequencing grade, Sigma-Aldrich) digestions
were performed overnight at room temperature in 0.1 M NH4HCO3 (pH 8).
Digests were analyzed by MALDI-TOF and LC–MS.
SDS-PAGE analysis. Proteins (2–5 µg) were mixed with 4× Laemmli sample buffer
supplemented with 2-mercaptoethanol (BioRad), boiled at 95 °C for 2–5 min and
loaded on an any kD™ Mini-PROTEAN® TGX™ precast protein gel (Biorad). The
Dual Color Precision Plus Protein™ Standard (BioRad) was used as reference. The
gel was run at 200 V, stained in 0.1% (w/v) Coomassie Brilliant Blue R250 solution
(10% (v/v) AcOH, 50% (v/v) MeOH in MilliQ water) and destained in destaining
solution (10% (v/v) AcOH, 50% (v/v) MeOH in MilliQ water) (see Supplementary
Fig. 28 for uncropped versions of the gels).
Data availability. All relevant data are available from the authors.
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